- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Letrozole
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 16,542
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Interventions
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Duarte, California • La Jolla, California • Denver, Colorado + 16 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Interventions
- BNT111, Cemiplimab
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more
- Conditions
- Breast Cancer
- Interventions
- Ovarian stimulation in vitro fertilization cryopreservation
- Procedure
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2018
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Acne Vulgaris
- Interventions
- ASC-J9 cream, placebo
- Drug
- Lead sponsor
- AndroScience Corp
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Fremont, California • San Diego, California • Boise, Idaho + 7 more
- Conditions
- Breast Carcinoma
- Interventions
- Biospecimen Collection, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
- Interventions
- Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2127399
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 16 more
- Conditions
- Breast Cancer, Carcinoma, Ductal
- Interventions
- Intra-Operative Radiotherapy (IORT), Lumpectomy, Whole Breast Radiotherapy, Intracavitary Brachytherapy, Accelerated External Beam 3-D Conformal Radiotherapy, Stereotactic APBI
- Radiation · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2029
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Rhabdomyosarcoma
- Interventions
- Not listed
- Lead sponsor
- Power Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Melanoma
- Interventions
- Sylatron, Yervoy
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
- Interventions
- Dexrazoxane, Doxorubicin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma
- Interventions
- ZK-EPO
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Breast Cancer
- Interventions
- Pembrolizumab, High-intensity focused ultrasound (HIFU)
- Drug · Device
- Lead sponsor
- Patrick Dillon, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advanced Ovarian Cancer, Triple Negative Breast Cancer
- Interventions
- Atezolizumab, RO6870810
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Atopic Dermatitis, Pruritus, Sleep Disturbance
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Psoriasis
- Interventions
- Placebo, 50 mg etanercept, 80 mg ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 41
- States / cities
- Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more
- Conditions
- Atopic Dermatitis
- Interventions
- EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%
- Device · Drug
- Lead sponsor
- Promius Pharma, LLC
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Winston-Salem, North Carolina + 2 more
- Conditions
- Alopecia Areata
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Breast Cancer
- Interventions
- Margetuximab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- San Francisco, California • Stanford, California • Plantation, Florida + 3 more
- Conditions
- Breast Cancer, Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,133,575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia
- Conditions
- Advanced Cancer
- Interventions
- LY3475070, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
- Interventions
- PRT1419
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more